Latest News

Researchers, including first author Samuel Wilkinson, MD, associate professor of psychiatry, and senior author Greg Rhee, PhD, associate professor adjunct in psychiatry, wrote in JAMA Psychiatry about the need to conduct clinical trials to prevent suicide.

A new device acquired by Yale Interventional Psychiatry Service has dramatically reduced the amount of time patients have to sit while undergoing transcranial magnetic stimulation for major depressive disorder.

Patients are now being recruited for a study to compare the effectiveness of IV ketamine and esketamine nasal spray (otherwise known as Spravato) for people who suffer from treatment-resistant depression.

Gustavo A. Angarita, MD, MHS; Joao P. De Aquino, MD; Matthew Girgenti, PhD; Elizabeth Goldfarb, PhD; and Rajiv Radhakrishnan, MD, have been elected to Associate Membership of the American College of Neuropsychopharmacology.

Gerard Sanacora, MD, PhD, George D. and Esther S. Gross Professor of Psychiatry, spoke to The New York Times about some common questions and misconceptions about antidepressants. Sanacora is director of the Yale Depression Research Program.

A Yale psychiatrist answers questions about electroconvulsive therapy (ECT), a psychiatric treatment that involves sending electrical currents through the brain.

A small sample of patients with bipolar disorder displayed noteworthy improvement in their depressive symptoms after being treated with the rapid-acting antidepressant intravenous ketamine and the nasal spray esketamine, according to a new Yale led-study. Mia Santucci, BA, postgraduate associate, and Samuel Wilkinson, MD, associate professor of psychiatry, are lead and senior authors, respectively.

Gerard Sanacora, MD, PhD, George D. and Esther S. Gross Professor of Psychiatry, spoke to The Wall Street Journal about ketamine's effect on the brain and why it can work as an antidepressant.

Announcing the winners of the 2024 Yale School of Medicine teaching awards.